JP2005506158A - 経皮パッチ - Google Patents

経皮パッチ Download PDF

Info

Publication number: JP2005506158A
Authority: JP; Japan
Prior art keywords: kit; skin; conductive fluid; current; electrochemical cell
Prior art date: 2001-10-24
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

JP2003537728A

Other languages

English (en)

Japanese (ja)

Other versions

JP2005506158A5 (zh

Inventor

ニッツァン，ズビ

グロス，ヨッシ

マブァー，ダニエラ

タマーキン，ダブ

Original Assignee

パワーペーパーリミティド

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-10-24

Filing date

2002-10-23

Publication date

2005-03-03

2002-10-23 Application filed by パワーペーパーリミティド filed Critical パワーペーパーリミティド

2005-03-03 Publication of JP2005506158A publication Critical patent/JP2005506158A/ja

2006-01-05 Publication of JP2005506158A5 publication Critical patent/JP2005506158A5/ja

Status Withdrawn legal-status Critical Current

Links

239000012530 fluid Substances 0.000 claims abstract description 87
239000000126 substance Substances 0.000 claims abstract description 76
239000000463 material Substances 0.000 claims description 34
239000003814 drug Substances 0.000 claims description 27
230000000638 stimulation Effects 0.000 claims description 17
230000017423 tissue regeneration Effects 0.000 claims description 12
230000000699 topical effect Effects 0.000 claims description 12
239000002537 cosmetic Substances 0.000 claims description 11
238000004520 electroporation Methods 0.000 claims description 11
239000000017 hydrogel Substances 0.000 claims description 11
239000000243 solution Substances 0.000 claims description 11
231100000241 scar Toxicity 0.000 claims description 10
238000001962 electrophoresis Methods 0.000 claims description 8
239000000499 gel Substances 0.000 claims description 8
230000029663 wound healing Effects 0.000 claims description 8
239000006071 cream Substances 0.000 claims description 7
239000003792 electrolyte Substances 0.000 claims description 7
239000006210 lotion Substances 0.000 claims description 7
229920003169 water-soluble polymer Polymers 0.000 claims description 7
235000013305 food Nutrition 0.000 claims description 6
239000007788 liquid Substances 0.000 claims description 6
230000007246 mechanism Effects 0.000 claims description 6
230000009467 reduction Effects 0.000 claims description 6
230000002265 prevention Effects 0.000 claims description 5
239000000725 suspension Substances 0.000 claims description 5
229940124597 therapeutic agent Drugs 0.000 claims description 5
239000000839 emulsion Substances 0.000 claims description 4
239000006072 paste Substances 0.000 claims description 4
239000003708 ampul Substances 0.000 claims description 3
230000003796 beauty Effects 0.000 claims description 3
208000010201 Exanthema Diseases 0.000 claims description 2
230000003444 anaesthetic effect Effects 0.000 claims description 2
201000005884 exanthem Diseases 0.000 claims description 2
206010037844 rash Diseases 0.000 claims description 2
239000011263 electroactive material Substances 0.000 claims 3
210000004027 cell Anatomy 0.000 description 66
239000010410 layer Substances 0.000 description 28
238000000034 method Methods 0.000 description 25
230000036982 action potential Effects 0.000 description 18
230000000694 effects Effects 0.000 description 17
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 15
208000002193 Pain Diseases 0.000 description 11
229940079593 drug Drugs 0.000 description 10
150000002500 ions Chemical class 0.000 description 10
210000003205 muscle Anatomy 0.000 description 10
210000001519 tissue Anatomy 0.000 description 10
239000000853 adhesive Substances 0.000 description 9
230000001070 adhesive effect Effects 0.000 description 9
230000004118 muscle contraction Effects 0.000 description 9
238000001827 electrotherapy Methods 0.000 description 8
230000028161 membrane depolarization Effects 0.000 description 7
210000005036 nerve Anatomy 0.000 description 7
239000000843 powder Substances 0.000 description 7
230000001225 therapeutic effect Effects 0.000 description 7
-1 acrylate ester Chemical class 0.000 description 6
230000004054 inflammatory process Effects 0.000 description 6
230000033001 locomotion Effects 0.000 description 6
229910052751 metal Inorganic materials 0.000 description 6
239000002184 metal Substances 0.000 description 6
230000037317 transdermal delivery Effects 0.000 description 6
230000001965 increasing effect Effects 0.000 description 5
210000004379 membrane Anatomy 0.000 description 5
239000012528 membrane Substances 0.000 description 5
230000004060 metabolic process Effects 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
206010061218 Inflammation Diseases 0.000 description 4
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
239000000654 additive Substances 0.000 description 4
239000012790 adhesive layer Substances 0.000 description 4
FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 4
230000008901 benefit Effects 0.000 description 4
239000002801 charged material Substances 0.000 description 4
230000006870 function Effects 0.000 description 4
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
239000000203 mixture Substances 0.000 description 4
201000004700 rosacea Diseases 0.000 description 4
238000002560 therapeutic procedure Methods 0.000 description 4
VNDYJBBGRKZCSX-UHFFFAOYSA-L zinc bromide Chemical compound Br[Zn]Br VNDYJBBGRKZCSX-UHFFFAOYSA-L 0.000 description 4
JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 4
BHHYHSUAOQUXJK-UHFFFAOYSA-L zinc fluoride Chemical compound F[Zn]F BHHYHSUAOQUXJK-UHFFFAOYSA-L 0.000 description 4
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 3
230000000996 additive effect Effects 0.000 description 3
229940035676 analgesics Drugs 0.000 description 3
239000000730 antalgic agent Substances 0.000 description 3
239000003963 antioxidant agent Substances 0.000 description 3
235000006708 antioxidants Nutrition 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
210000000988 bone and bone Anatomy 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
239000007933 dermal patch Substances 0.000 description 3
238000013461 design Methods 0.000 description 3
238000009792 diffusion process Methods 0.000 description 3
238000009472 formulation Methods 0.000 description 3
239000003193 general anesthetic agent Substances 0.000 description 3
230000035876 healing Effects 0.000 description 3
230000006872 improvement Effects 0.000 description 3
229960002715 nicotine Drugs 0.000 description 3
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 3
238000007639 printing Methods 0.000 description 3
230000008569 process Effects 0.000 description 3
230000004044 response Effects 0.000 description 3
230000002441 reversible effect Effects 0.000 description 3
230000004936 stimulating effect Effects 0.000 description 3
238000012360 testing method Methods 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 2
244000281702 Dioscorea villosa Species 0.000 description 2
QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
102000004877 Insulin Human genes 0.000 description 2
108090001061 Insulin Proteins 0.000 description 2
241001303601 Rosacea Species 0.000 description 2
206010043189 Telangiectasia Diseases 0.000 description 2
IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 2
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
239000013543 active substance Substances 0.000 description 2
229940035674 anesthetics Drugs 0.000 description 2
230000000840 anti-viral effect Effects 0.000 description 2
239000002220 antihypertensive agent Substances 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
239000002876 beta blocker Substances 0.000 description 2
229940097320 beta blocking agent Drugs 0.000 description 2
230000032823 cell division Effects 0.000 description 2
210000000170 cell membrane Anatomy 0.000 description 2
230000008602 contraction Effects 0.000 description 2
229940095074 cyclic amp Drugs 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
238000003745 diagnosis Methods 0.000 description 2
238000010494 dissociation reaction Methods 0.000 description 2
230000005593 dissociations Effects 0.000 description 2
238000012377 drug delivery Methods 0.000 description 2
230000005684 electric field Effects 0.000 description 2
230000005611 electricity Effects 0.000 description 2
238000005370 electroosmosis Methods 0.000 description 2
230000008020 evaporation Effects 0.000 description 2
238000001704 evaporation Methods 0.000 description 2
239000000284 extract Substances 0.000 description 2
239000011888 foil Substances 0.000 description 2
230000002496 gastric effect Effects 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
229940125396 insulin Drugs 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 2
210000003470 mitochondria Anatomy 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
229910000480 nickel oxide Inorganic materials 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
GNRSAWUEBMWBQH-UHFFFAOYSA-N oxonickel Chemical compound [Ni]=O GNRSAWUEBMWBQH-UHFFFAOYSA-N 0.000 description 2
238000000059 patterning Methods 0.000 description 2
230000035515 penetration Effects 0.000 description 2
230000010412 perfusion Effects 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
239000011148 porous material Substances 0.000 description 2
SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Chemical compound [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 description 2
238000005507 spraying Methods 0.000 description 2
210000003699 striated muscle Anatomy 0.000 description 2
239000000758 substrate Substances 0.000 description 2
208000009056 telangiectasis Diseases 0.000 description 2
230000001960 triggered effect Effects 0.000 description 2
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
230000002747 voluntary effect Effects 0.000 description 2
229940102001 zinc bromide Drugs 0.000 description 2
239000011592 zinc chloride Substances 0.000 description 2
235000005074 zinc chloride Nutrition 0.000 description 2
XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 1
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 1
METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
CIGPQLJUBWRNNX-UHFFFAOYSA-N 1-morpholin-4-yldodecan-1-one Chemical compound CCCCCCCCCCCC(=O)N1CCOCC1 CIGPQLJUBWRNNX-UHFFFAOYSA-N 0.000 description 1
LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
239000005541 ACE inhibitor Substances 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
244000144927 Aloe barbadensis Species 0.000 description 1
235000002961 Aloe barbadensis Nutrition 0.000 description 1
229940127291 Calcium channel antagonist Drugs 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
229920000049 Carbon (fiber) Polymers 0.000 description 1
206010007559 Cardiac failure congestive Diseases 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
239000004971 Cross linker Substances 0.000 description 1
ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
235000002723 Dioscorea alata Nutrition 0.000 description 1
235000007056 Dioscorea composita Nutrition 0.000 description 1
235000009723 Dioscorea convolvulacea Nutrition 0.000 description 1
235000005362 Dioscorea floribunda Nutrition 0.000 description 1
235000004868 Dioscorea macrostachya Nutrition 0.000 description 1
235000005361 Dioscorea nummularia Nutrition 0.000 description 1
235000005360 Dioscorea spiculiflora Nutrition 0.000 description 1
235000000504 Dioscorea villosa Nutrition 0.000 description 1
JRWZLRBJNMZMFE-UHFFFAOYSA-N Dobutamine Chemical compound C=1C=C(O)C(O)=CC=1CCNC(C)CCC1=CC=C(O)C=C1 JRWZLRBJNMZMFE-UHFFFAOYSA-N 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
102000018997 Growth Hormone Human genes 0.000 description 1
108010051696 Growth Hormone Proteins 0.000 description 1
241000208680 Hamamelis mollis Species 0.000 description 1
206010019280 Heart failures Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
235000006350 Ipomoea batatas var. batatas Nutrition 0.000 description 1
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
208000019695 Migraine disease Diseases 0.000 description 1
STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
206010035148 Plague Diseases 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
229920001273 Polyhydroxy acid Polymers 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
239000004820 Pressure-sensitive adhesive Substances 0.000 description 1
208000003251 Pruritus Diseases 0.000 description 1
206010039897 Sedation Diseases 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
239000000150 Sympathomimetic Substances 0.000 description 1
206010043376 Tetanus Diseases 0.000 description 1
244000269722 Thea sinensis Species 0.000 description 1
AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
238000003848 UV Light-Curing Methods 0.000 description 1
229930003268 Vitamin C Natural products 0.000 description 1
229930003427 Vitamin E Natural products 0.000 description 1
241000607479 Yersinia pestis Species 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
238000011374 additional therapy Methods 0.000 description 1
239000008272 agar Substances 0.000 description 1
230000032683 aging Effects 0.000 description 1
239000000556 agonist Substances 0.000 description 1
NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
230000001476 alcoholic effect Effects 0.000 description 1
SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
235000019169 all-trans-retinol Nutrition 0.000 description 1
239000011717 all-trans-retinol Substances 0.000 description 1
235000011399 aloe vera Nutrition 0.000 description 1
229940061720 alpha hydroxy acid Drugs 0.000 description 1
150000001280 alpha hydroxy acids Chemical class 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
150000001408 amides Chemical group 0.000 description 1
PECIYKGSSMCNHN-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=NC=N[C]21.O=C1N(C)C(=O)N(C)C2=NC=N[C]21 PECIYKGSSMCNHN-UHFFFAOYSA-N 0.000 description 1
229960003556 aminophylline Drugs 0.000 description 1
239000002269 analeptic agent Substances 0.000 description 1
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
230000000578 anorexic effect Effects 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000003712 anti-aging effect Effects 0.000 description 1
230000001088 anti-asthma Effects 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
230000001078 anti-cholinergic effect Effects 0.000 description 1
229940127003 anti-diabetic drug Drugs 0.000 description 1
230000003474 anti-emetic effect Effects 0.000 description 1
230000002924 anti-infective effect Effects 0.000 description 1
229940124599 anti-inflammatory drug Drugs 0.000 description 1
229940035678 anti-parkinson drug Drugs 0.000 description 1
230000001153 anti-wrinkle effect Effects 0.000 description 1
239000003416 antiarrhythmic agent Substances 0.000 description 1
229940124347 antiarthritic drug Drugs 0.000 description 1
239000000924 antiasthmatic agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
229940125681 anticonvulsant agent Drugs 0.000 description 1
239000001961 anticonvulsive agent Substances 0.000 description 1
239000000935 antidepressant agent Substances 0.000 description 1
229940005513 antidepressants Drugs 0.000 description 1
239000003472 antidiabetic agent Substances 0.000 description 1
239000003793 antidiarrheal agent Substances 0.000 description 1
239000002111 antiemetic agent Substances 0.000 description 1
229940125683 antiemetic agent Drugs 0.000 description 1
229940125715 antihistaminic agent Drugs 0.000 description 1
239000000739 antihistaminic agent Substances 0.000 description 1
229940030600 antihypertensive agent Drugs 0.000 description 1
229940127088 antihypertensive drug Drugs 0.000 description 1
229960005475 antiinfective agent Drugs 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
229940041181 antineoplastic drug Drugs 0.000 description 1
239000000939 antiparkinson agent Substances 0.000 description 1
239000000164 antipsychotic agent Substances 0.000 description 1
239000002221 antipyretic Substances 0.000 description 1
239000003443 antiviral agent Substances 0.000 description 1
229940121357 antivirals Drugs 0.000 description 1
239000002830 appetite depressant Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
230000000712 assembly Effects 0.000 description 1
238000000429 assembly Methods 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
229960002274 atenolol Drugs 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
150000001277 beta hydroxy acids Chemical class 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
229960001736 buprenorphine Drugs 0.000 description 1
RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
229910001622 calcium bromide Inorganic materials 0.000 description 1
239000000480 calcium channel blocker Substances 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
WGEFECGEFUFIQW-UHFFFAOYSA-L calcium dibromide Chemical compound [Ca+2].[Br-].[Br-] WGEFECGEFUFIQW-UHFFFAOYSA-L 0.000 description 1
239000004917 carbon fiber Substances 0.000 description 1
229940124461 cardiostimulant Drugs 0.000 description 1
239000002327 cardiovascular agent Substances 0.000 description 1
229940125692 cardiovascular agent Drugs 0.000 description 1
235000021466 carotenoid Nutrition 0.000 description 1
150000001747 carotenoids Chemical class 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000033077 cellular process Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000000812 cholinergic antagonist Substances 0.000 description 1
229940124579 cold medicine Drugs 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
239000004020 conductor Substances 0.000 description 1
238000010276 construction Methods 0.000 description 1
230000002920 convulsive effect Effects 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
210000004351 coronary vessel Anatomy 0.000 description 1
238000001723 curing Methods 0.000 description 1
206010061428 decreased appetite Diseases 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
239000007854 depigmenting agent Substances 0.000 description 1
230000008021 deposition Effects 0.000 description 1
229960002086 dextran Drugs 0.000 description 1
229960000633 dextran sulfate Drugs 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
239000003989 dielectric material Substances 0.000 description 1
235000004879 dioscorea Nutrition 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
238000002845 discoloration Methods 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000002934 diuretic Substances 0.000 description 1
229940030606 diuretics Drugs 0.000 description 1
229960001089 dobutamine Drugs 0.000 description 1
230000035622 drinking Effects 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
230000008482 dysregulation Effects 0.000 description 1
230000002500 effect on skin Effects 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
210000001723 extracellular space Anatomy 0.000 description 1
239000004744 fabric Substances 0.000 description 1
229960002428 fentanyl Drugs 0.000 description 1
IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 1
239000000835 fiber Substances 0.000 description 1
230000005669 field effect Effects 0.000 description 1
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
230000014509 gene expression Effects 0.000 description 1
239000008103 glucose Substances 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
229910052737 gold Inorganic materials 0.000 description 1
239000010931 gold Substances 0.000 description 1
235000009569 green tea Nutrition 0.000 description 1
238000009499 grossing Methods 0.000 description 1
239000000122 growth hormone Substances 0.000 description 1
230000036541 health Effects 0.000 description 1
230000020169 heat generation Effects 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229920002674 hyaluronan Polymers 0.000 description 1
229960003160 hyaluronic acid Drugs 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
229920001600 hydrophobic polymer Polymers 0.000 description 1
150000001261 hydroxy acids Chemical class 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
230000002102 hyperpolarization Effects 0.000 description 1
239000003326 hypnotic agent Substances 0.000 description 1
230000000147 hypnotic effect Effects 0.000 description 1
229960003444 immunosuppressant agent Drugs 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
239000003999 initiator Substances 0.000 description 1
208000014674 injury Diseases 0.000 description 1
230000030214 innervation Effects 0.000 description 1
238000009413 insulation Methods 0.000 description 1
210000003093 intracellular space Anatomy 0.000 description 1
230000007794 irritation Effects 0.000 description 1
238000003475 lamination Methods 0.000 description 1
229910000464 lead oxide Inorganic materials 0.000 description 1
229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 description 1
210000004324 lymphatic system Anatomy 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
230000025350 membrane depolarization involved in regulation of action potential Effects 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
150000002739 metals Chemical class 0.000 description 1
VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
206010027599 migraine Diseases 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
230000001483 mobilizing effect Effects 0.000 description 1
230000003020 moisturizing effect Effects 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
201000003152 motion sickness Diseases 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
210000000663 muscle cell Anatomy 0.000 description 1
229940035363 muscle relaxants Drugs 0.000 description 1
239000003158 myorelaxant agent Substances 0.000 description 1
230000002232 neuromuscular Effects 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
229960001597 nifedipine Drugs 0.000 description 1
HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
239000012811 non-conductive material Substances 0.000 description 1
238000007645 offset printing Methods 0.000 description 1
229960005343 ondansetron Drugs 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
YEXPOXQUZXUXJW-UHFFFAOYSA-N oxolead Chemical compound [Pb]=O YEXPOXQUZXUXJW-UHFFFAOYSA-N 0.000 description 1
229940094443 oxytocics prostaglandins Drugs 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
230000001734 parasympathetic effect Effects 0.000 description 1
239000000734 parasympathomimetic agent Substances 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000037361 pathway Effects 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
150000002978 peroxides Chemical class 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
229940127557 pharmaceutical product Drugs 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000004033 plastic Substances 0.000 description 1
239000004014 plasticizer Substances 0.000 description 1
229910052697 platinum Inorganic materials 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
239000004584 polyacrylic acid Substances 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
235000011056 potassium acetate Nutrition 0.000 description 1
229910000160 potassium phosphate Inorganic materials 0.000 description 1
235000011009 potassium phosphates Nutrition 0.000 description 1
238000010248 power generation Methods 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
239000003368 psychostimulant agent Substances 0.000 description 1
238000010526 radical polymerization reaction Methods 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
229930002330 retinoic acid Natural products 0.000 description 1
235000020944 retinol Nutrition 0.000 description 1
239000011607 retinol Substances 0.000 description 1
229960003471 retinol Drugs 0.000 description 1
229960001634 ritodrine Drugs 0.000 description 1
IOVGROKTTNBUGK-SJCJKPOMSA-N ritodrine Chemical compound N([C@@H](C)[C@H](O)C=1C=CC(O)=CC=1)CCC1=CC=C(O)C=C1 IOVGROKTTNBUGK-SJCJKPOMSA-N 0.000 description 1
229960002052 salbutamol Drugs 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
229960002646 scopolamine Drugs 0.000 description 1
STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
230000036280 sedation Effects 0.000 description 1
230000035807 sensation Effects 0.000 description 1
230000001953 sensory effect Effects 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
229910001923 silver oxide Inorganic materials 0.000 description 1
210000002027 skeletal muscle Anatomy 0.000 description 1
231100000046 skin rash Toxicity 0.000 description 1
230000005586 smoking cessation Effects 0.000 description 1
239000002195 soluble material Substances 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
238000003860 storage Methods 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
GGCSSNBKKAUURC-UHFFFAOYSA-N sufentanil Chemical compound C1CN(CCC=2SC=CC=2)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 GGCSSNBKKAUURC-UHFFFAOYSA-N 0.000 description 1
229960004739 sufentanil Drugs 0.000 description 1
230000008961 swelling Effects 0.000 description 1
229940127230 sympathomimetic drug Drugs 0.000 description 1
230000005062 synaptic transmission Effects 0.000 description 1
230000002123 temporal effect Effects 0.000 description 1
229960000195 terbutaline Drugs 0.000 description 1
239000010409 thin film Substances 0.000 description 1
239000005495 thyroid hormone Substances 0.000 description 1
229940036555 thyroid hormone Drugs 0.000 description 1
230000000451 tissue damage Effects 0.000 description 1
231100000827 tissue damage Toxicity 0.000 description 1
229910052719 titanium Inorganic materials 0.000 description 1
239000010936 titanium Substances 0.000 description 1
231100000167 toxic agent Toxicity 0.000 description 1
238000012549 training Methods 0.000 description 1
239000003204 tranquilizing agent Substances 0.000 description 1
230000002936 tranquilizing effect Effects 0.000 description 1
230000008733 trauma Effects 0.000 description 1
229960001727 tretinoin Drugs 0.000 description 1
238000009827 uniform distribution Methods 0.000 description 1
229940124549 vasodilator Drugs 0.000 description 1
239000003071 vasodilator agent Substances 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
235000019154 vitamin C Nutrition 0.000 description 1
239000011718 vitamin C Substances 0.000 description 1
235000019165 vitamin E Nutrition 0.000 description 1
229940046009 vitamin E Drugs 0.000 description 1
239000011709 vitamin E Substances 0.000 description 1
150000003722 vitamin derivatives Chemical class 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
229940118846 witch hazel Drugs 0.000 description 1

Images

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/20—Applying electric currents by contact electrodes continuous direct currents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/0404—Electrodes for external use
- A61N1/0408—Use-related aspects
- A61N1/0428—Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
- A61N1/0432—Anode and cathode
- A61N1/044—Shape of the electrode
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/0404—Electrodes for external use
- A61N1/0408—Use-related aspects
- A61N1/0428—Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
- A61N1/0448—Drug reservoir
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/325—Applying electric currents by contact electrodes alternating or intermittent currents for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Biomedical Technology (AREA)
Radiology & Medical Imaging (AREA)
Neurology (AREA)
Physical Education & Sports Medicine (AREA)
Dermatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurosurgery (AREA)
Hematology (AREA)
Diabetes (AREA)
Pain & Pain Management (AREA)
Obesity (AREA)
Electrotherapy Devices (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Media Introduction/Drainage Providing Device (AREA)

JP2003537728A 2001-10-24 2002-10-23 経皮パッチ Withdrawn JP2005506158A (ja)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US33052601P	2001-10-24	2001-10-24
PCT/IL2002/000848 WO2003035166A2 (en)	2001-10-24	2002-10-23	Dermal patch

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2009260129A Division JP2010075710A (ja)	2001-10-24	2009-11-13	経皮パッチ

Publications (2)

Publication Number	Publication Date
JP2005506158A true JP2005506158A (ja)	2005-03-03
JP2005506158A5 JP2005506158A5 (zh)	2006-01-05

Family

ID=23290151

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
JP2003537728A Withdrawn JP2005506158A (ja)	2001-10-24	2002-10-23	経皮パッチ
JP2009260129A Pending JP2010075710A (ja)	2001-10-24	2009-11-13	経皮パッチ

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
JP2009260129A Pending JP2010075710A (ja)	2001-10-24	2009-11-13	経皮パッチ

Country Status (8)

Country	Link
EP (1)	EP1438099A2 (zh)
JP (2)	JP2005506158A (zh)
KR (1)	KR20040053184A (zh)
CN (1)	CN1607970B (zh)
AU (1)	AU2002347567B2 (zh)
CA (1)	CA2464301A1 (zh)
RU (2)	RU2320378C2 (zh)
WO (1)	WO2003035166A2 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2007233337A (ja) *	2006-02-02	2007-09-13	Seiko Epson Corp	電気泳動表示装置及び電子機器

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7643874B2 (en)	2001-10-24	2010-01-05	Power Paper Ltd.	Dermal patch
JP2007504882A (ja) *	2003-09-10	2007-03-08	パワーペーパーリミティド	使い捨て電気包帯
GB2432322B (en) *	2003-09-30	2007-11-28	Synapse Medical Solutions Ltd	Gel for tissue treatment
GB2432321B (en) *	2003-09-30	2007-10-17	Synapse Medical Solutions Ltd	Dressing for tissue treatment
KR100837083B1 (ko) *	2007-02-28	2008-06-11	김종택	피부 흡수 향상 장치
SE535589C2 (sv) *	2010-07-12	2012-10-02	Moelnlycke Health Care Ab	Sårförband innefattande ledande region
US20130338470A1 (en) *	2011-03-02	2013-12-19	Koninklijke Philips N.V.	Dry skin conductance electrode
US10451897B2 (en)	2011-03-18	2019-10-22	Johnson & Johnson Vision Care, Inc.	Components with multiple energization elements for biomedical devices
EP2729212B1 (en) *	2011-07-08	2017-09-06	The Cleveland Clinic Foundation	System for wound healing
US8857983B2 (en)	2012-01-26	2014-10-14	Johnson & Johnson Vision Care, Inc.	Ophthalmic lens assembly having an integrated antenna structure
CN102836503A (zh) *	2012-09-19	2012-12-26	龙丹	一种新型敷贴综合治疗仪
US10537703B2 (en)	2012-11-26	2020-01-21	Thync Global, Inc.	Systems and methods for transdermal electrical stimulation to improve sleep
US10485972B2 (en)	2015-02-27	2019-11-26	Thync Global, Inc.	Apparatuses and methods for neuromodulation
US11033731B2 (en)	2015-05-29	2021-06-15	Thync Global, Inc.	Methods and apparatuses for transdermal electrical stimulation
US10814131B2 (en)	2012-11-26	2020-10-27	Thync Global, Inc.	Apparatuses and methods for neuromodulation
US9474891B2 (en) *	2014-05-25	2016-10-25	Thync Global, Inc.	Transdermal neurostimulator adapted to reduce capacitive build-up
RU2534521C2 (ru) *	2012-11-27	2014-11-27	Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Национальный исследовательский Томский государственный университет" (ТГУ)	Способ трансдермального введения инсулина и устройство для его осуществления
KR101445005B1 (ko) *	2012-12-24	2014-09-26	김경원	감염성 및 비감염성 염증질환 치료용 패치 키트 및 이의 용도
HK1222316A1 (zh) *	2013-05-02	2017-06-30	Vomaris Innovations, Inc.	可伸展的傷口敷料
US10293161B2 (en)	2013-06-29	2019-05-21	Thync Global, Inc.	Apparatuses and methods for transdermal electrical stimulation of nerves to modify or induce a cognitive state
CN103611215B (zh) *	2013-12-04	2016-08-10	天津中环创新科技有限公司	智能超薄柔性电子自动给药贴
US10381687B2 (en)	2014-08-21	2019-08-13	Johnson & Johnson Vision Care, Inc.	Methods of forming biocompatible rechargable energization elements for biomedical devices
US10361404B2 (en)	2014-08-21	2019-07-23	Johnson & Johnson Vision Care, Inc.	Anodes for use in biocompatible energization elements
US10627651B2 (en)	2014-08-21	2020-04-21	Johnson & Johnson Vision Care, Inc.	Methods and apparatus to form biocompatible energization primary elements for biomedical devices with electroless sealing layers
US9383593B2 (en)	2014-08-21	2016-07-05	Johnson & Johnson Vision Care, Inc.	Methods to form biocompatible energization elements for biomedical devices comprising laminates and placed separators
US9715130B2 (en)	2014-08-21	2017-07-25	Johnson & Johnson Vision Care, Inc.	Methods and apparatus to form separators for biocompatible energization elements for biomedical devices
US9599842B2 (en)	2014-08-21	2017-03-21	Johnson & Johnson Vision Care, Inc.	Device and methods for sealing and encapsulation for biocompatible energization elements
US9941547B2 (en)	2014-08-21	2018-04-10	Johnson & Johnson Vision Care, Inc.	Biomedical energization elements with polymer electrolytes and cavity structures
US10361405B2 (en)	2014-08-21	2019-07-23	Johnson & Johnson Vision Care, Inc.	Biomedical energization elements with polymer electrolytes
CA2900271A1 (en) *	2014-08-21	2016-02-21	Johnson & Johnson Vision Care, Inc.	Components with multiple energization elements for biomedical devices
US9793536B2 (en)	2014-08-21	2017-10-17	Johnson & Johnson Vision Care, Inc.	Pellet form cathode for use in a biocompatible battery
PL3191170T3 (pl) *	2014-09-08	2022-06-27	Fastmeditalia S.R.L.	Plaster zdolny do wytwarzania mikroprądów
US20160089535A1 (en) *	2014-09-29	2016-03-31	Elc Management Llc	Targeted And Individualized Delivery Of Skincare Treatments With Micro-Current In A Mask Or Patch Form
US11534608B2 (en)	2015-01-04	2022-12-27	Ist, Llc	Methods and apparatuses for transdermal stimulation of the outer ear
WO2016109851A1 (en)	2015-01-04	2016-07-07	Thync, Inc.	Methods and apparatuses for transdermal stimulation of the outer ear
US10258788B2 (en)	2015-01-05	2019-04-16	Thync Global, Inc.	Electrodes having surface exclusions
CN104784817A (zh) *	2015-04-19	2015-07-22	通化市佳俊生物电子有限公司	理化反应直流电治疗贴
WO2017106878A1 (en)	2015-12-18	2017-06-22	Thync Global, Inc.	Apparatuses and methods for transdermal electrical stimulation of nerves to modify or induce a cognitive state
CN105709331A (zh) *	2016-01-19	2016-06-29	云南科威液态金属谷研发有限公司	一种理疗医用电极
US10345620B2 (en)	2016-02-18	2019-07-09	Johnson & Johnson Vision Care, Inc.	Methods and apparatus to form biocompatible energization elements incorporating fuel cells for biomedical devices
US10646708B2 (en)	2016-05-20	2020-05-12	Thync Global, Inc.	Transdermal electrical stimulation at the neck
KR101897174B1 (ko) *	2016-08-17	2018-09-12	(주)오스힐	연부조직질환 치료용 경피약물전달 촉진장치
CN107029343B (zh)	2017-01-18	2018-11-23	常州华佳医疗器械有限公司	一种便捷式透皮给药贴片器械及其制备方法
EP3459588A1 (en) *	2017-09-20	2019-03-27	L'oreal	Electrical method of delivering hyaluronic acid through the skin
KR102004208B1 (ko)	2017-10-30	2019-07-29	주식회사 애니테이프	자외선 차단 기능이 있는 하이드로-콜로이드 핫멜트 습윤성 드레싱 테이프의 제조 방법
KR102004212B1 (ko)	2018-02-28	2019-07-29	주식회사 애니테이프	흡수력이 향상된 하이드로-콜로이드 핫멜트 습윤성 드레싱 테이프의 제조 방법
WO2019185168A1 (en) *	2018-03-30	2019-10-03	L'oreal	Electroporation of hyaluronic acid and heating
WO2019209969A1 (en)	2018-04-24	2019-10-31	Thync Global, Inc.	Streamlined and pre-set neuromodulators
KR20200068195A (ko)	2018-12-05	2020-06-15	주식회사 애니 테이프	피부 첩부용 패치
CN110772378A (zh) *	2019-10-31	2020-02-11	京东方科技集团股份有限公司	敷料
WO2024185659A1 (ja) *	2023-03-09	2024-09-12	株式会社 Mtg	電気刺激装置

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4856188A (en) *	1984-10-12	1989-08-15	Drug Delivery Systems Inc.	Method for making disposable and/or replenishable transdermal drug applicators
US5899856A (en)	1988-09-08	1999-05-04	Sudormed, Inc.	Dermal patch detecting long-term alcohol consumption and method of use
US5248295A (en)	1989-05-08	1993-09-28	Iomed, Inc.	Bioelectrode seal
US4968297A (en)	1989-05-09	1990-11-06	Iomec, Inc.	Iontophoretic electrode with solution containment system
DE4014913C2 (de) *	1990-05-10	1996-05-15	Lohmann Therapie Syst Lts	Miniaturisiertes transdermales therapeutisches System für die Iontophorese
US6238381B1 (en) *	1990-11-01	2001-05-29	Robert Tapper	Iontophoretic treatment system
US5897522A (en) *	1995-12-20	1999-04-27	Power Paper Ltd.	Flexible thin layer open electrochemical cell and applications of same
US5652043A (en) *	1995-12-20	1997-07-29	Baruch Levanon	Flexible thin layer open electrochemical cell
US5601618A (en) *	1996-02-26	1997-02-11	James; Brian C.	Stimulation and heating device
US5836942A (en) *	1996-04-04	1998-11-17	Minnesota Mining And Manufacturing Company	Biomedical electrode with lossy dielectric properties
ZA974576B (en)	1996-06-04	1998-02-04	Farmarc Nederland Bv	Pharmaceutical composition.
US5800685A (en) *	1996-10-28	1998-09-01	Cardiotronics Systems, Inc.	Electrically conductive adhesive hydrogels
FR2778108B1 (fr) *	1998-04-30	2000-07-21	Lhd Lab Hygiene Dietetique	Dispositif d'administration transdermique de medicament par ionophorese
AU4696499A (en)	1998-06-19	2000-01-05	Genetronics, Inc.	Electrically assisted transdermal method and apparatus for the treatment of erectile dysfunction
RU2156142C1 (ru) *	1999-04-15	2000-09-20	Соболев Вадим Иванович	Устройство для проведения электрофореза
WO2000071108A2 (en)	1999-05-20	2000-11-30	Sepracor Inc.	Methods for treatment of asthma using s-oxybutynin
US6421561B1 (en) *	1999-12-30	2002-07-16	Birch Point Medical, Inc.	Rate adjustable drug delivery system
US6291677B1 (en)	2000-08-29	2001-09-18	Allergan Sales, Inc.	Compounds having activity as inhibitors of cytochrome P450RAI

2002
- 2002-10-23 JP JP2003537728A patent/JP2005506158A/ja not_active Withdrawn
- 2002-10-23 EP EP02783494A patent/EP1438099A2/en not_active Ceased
- 2002-10-23 WO PCT/IL2002/000848 patent/WO2003035166A2/en active Application Filing
- 2002-10-23 RU RU2004112542/14A patent/RU2320378C2/ru not_active IP Right Cessation
- 2002-10-23 AU AU2002347567A patent/AU2002347567B2/en not_active Ceased
- 2002-10-23 CN CN028260759A patent/CN1607970B/zh not_active Expired - Fee Related
- 2002-10-23 CA CA002464301A patent/CA2464301A1/en not_active Abandoned
- 2002-10-23 KR KR10-2004-7005747A patent/KR20040053184A/ko not_active Abandoned
2007
- 2007-10-19 RU RU2007138942/14A patent/RU2007138942A/ru not_active Application Discontinuation
2009
- 2009-11-13 JP JP2009260129A patent/JP2010075710A/ja active Pending

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2007233337A (ja) *	2006-02-02	2007-09-13	Seiko Epson Corp	電気泳動表示装置及び電子機器

Also Published As

Publication number	Publication date
HK1074808A1 (zh)	2005-11-25
WO2003035166A2 (en)	2003-05-01
AU2002347567B2 (en)	2008-07-17
EP1438099A2 (en)	2004-07-21
CN1607970A (zh)	2005-04-20
KR20040053184A (ko)	2004-06-23
RU2007138942A (ru)	2009-04-27
WO2003035166A3 (en)	2004-03-18
RU2320378C2 (ru)	2008-03-27
RU2004112542A (ru)	2005-03-10
CN1607970B (zh)	2010-11-10
CA2464301A1 (en)	2003-05-01
JP2010075710A (ja)	2010-04-08

Publication	Publication Date	Title
US7643874B2 (en)	2010-01-05	Dermal patch
JP2005506158A (ja)	2005-03-03	経皮パッチ
US7979117B2 (en)	2011-07-12	Device and method for controlled delivery of active substance into the skin
AU2002347567A1 (en)	2003-07-03	Dermal patch
AU2002363106A1 (en)	2003-07-03	Device and method for controlled delivery of active substance into the skin
AU2004255059B2 (en)	2010-11-11	Method, apparatus, and kit for onychomycosis treatment using electrokinetic transport of substances
US20070016277A1 (en)	2007-01-18	Lip augmentation device
US20100228180A1 (en)	2010-09-09	Power Source Electrode Treatment Device
US20060264804A1 (en)	2006-11-23	Device and kit for delivery of encapsulated substances and methods of use thereof
US20090287208A1 (en)	2009-11-19	Electrolytic tissue treatment
KR200403033Y1 (ko)	2005-12-07	피부팩용 휴대형 피부미용기기
WO2006072834A2 (en)	2006-07-13	Stable electrode and uses thereof
HK1074808B (zh)	2011-08-12	皮膚貼片
KR20230091270A (ko)	2023-06-23	미세전류를 활용해 피부세포를 자극함으로써 안티에이징 효과를 극대화한 콜라겐 생성 휴대용 미용기기

Legal Events

Date	Code	Title	Description
2005-10-25	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20051024
2005-10-25	A621	Written request for application examination	Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20051024
2008-12-10	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20081209
2009-03-07	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090306
2009-03-16	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090313
2009-06-10	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090609
2009-07-15	A02	Decision of refusal	Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090714
2009-11-14	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091113
2009-12-09	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091118
2009-12-15	A911	Transfer to examiner for re-examination before appeal (zenchi)	Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20091214
2009-12-22	A761	Written withdrawal of application	Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20091221

JP2005506158A - 経皮パッチ - Google Patents

Info

Links

Images

Classifications

Landscapes

Applications Claiming Priority (2)

Related Child Applications (1)

Publications (2)

Family

ID=23290151

Family Applications (2)

Family Applications After (1)

Country Status (8)

Cited By (1)

Families Citing this family (51)

Family Cites Families (18)

Cited By (1)

Also Published As

Similar Documents

Legal Events